Wedbush Has Negative Outlook for Inozyme Pharma Q2 Earnings

Inozyme Pharma, Inc. (NASDAQ:INZY) – Equities research analysts at Wedbush cut their Q2 2025 earnings estimates for shares of Inozyme Pharma in a note issued to investors on Wednesday, May 14th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.34) per share for the quarter, down from their previous forecast of ($0.25). Wedbush currently has a “Outperform” rating and a $7.00 target price on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. Wedbush also issued estimates for Inozyme Pharma’s FY2025 earnings at ($1.23) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.00) EPS and FY2027 earnings at ($0.79) EPS.

A number of other brokerages have also recently issued reports on INZY. Piper Sandler decreased their price objective on shares of Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Wells Fargo & Company restated an “equal weight” rating and set a $4.00 price objective on shares of Inozyme Pharma in a report on Friday. Raymond James decreased their price objective on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a report on Wednesday, March 12th. Jefferies Financial Group restated a “hold” rating and set a $4.00 price objective (down previously from $15.00) on shares of Inozyme Pharma in a report on Friday. Finally, Needham & Company LLC decreased their price objective on shares of Inozyme Pharma from $15.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Inozyme Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.75.

Inozyme Pharma Stock Up 178.2%

Shares of NASDAQ:INZY opened at $3.95 on Friday. The stock has a market cap of $255.02 million, a price-to-earnings ratio of -2.53 and a beta of 1.35. The company has a 50 day moving average of $1.09 and a 200-day moving average of $1.89. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. Inozyme Pharma has a one year low of $0.72 and a one year high of $6.24.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01).

Institutional Trading of Inozyme Pharma

A number of institutional investors have recently modified their holdings of the company. Barclays PLC raised its position in Inozyme Pharma by 261.4% in the 3rd quarter. Barclays PLC now owns 76,730 shares of the company’s stock valued at $401,000 after buying an additional 55,497 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Inozyme Pharma by 31.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company’s stock worth $151,000 after acquiring an additional 6,851 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Inozyme Pharma in the fourth quarter valued at approximately $38,000. abrdn plc bought a new stake in shares of Inozyme Pharma in the fourth quarter worth $472,000. Finally, Palumbo Wealth Management LLC lifted its position in shares of Inozyme Pharma by 52.3% in the fourth quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock worth $64,000 after purchasing an additional 7,995 shares in the last quarter. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.